kwic
clinical
clinical
right
off
ON
25
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for clinical out of >500 occurrences
554339 occurrences (No.20 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to clinical]
554339 occurrences (No.20 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 25) As canine mammary tumours (CMT) and human breast cancer share clinical and prognostic features, the former have been proposed as a model to study carcinogenesis and improved therapeutic treatment in human breast cancer. |
| PMID:23510405 DOI:10.1111/vco.12028 |
| 2015 Veterinary and comparative oncology |
| * Expression and functionality of TRPV1 receptor in human MCF-7 and canine CF.41 cells. |
| - As canine mammary tumours (CMT) and human breast cancer share clinical and prognostic features, the former have been proposed as a model to study carcinogenesis and improved therapeutic treatment in human breast cancer. In recent years, it has been shown that transient receptor potential vanilloid 1 (TRPV1) is expressed in different neoplastic tissues and its activation has been associated with regulation of cancer growth and progression. The aim of the present research was to demonstrate the presence of TRPV1 in human and canine mammary cancer cells, MCF-7 and CF.41, respectively, and to study the role of TRPV1 in regulating cell proliferation. The images obtained by Western blot showed a signal at 100 kDa corresponding to the molecular weight of TRPV1 receptor. All tested TRPV1 agonists and antagonists caused a significant decrease (P < 0.05) of cell growth rate in MCF-7 cells. By contrast, in CF.41 cells capsaicin and capsazepine induced a significant increase (P < 0.05) in cell proliferation, whereas resiniferatoxin (RTX) and 5-iodo-resiniferatoxin (5-I-RTX) had no influence on CF.41 cell proliferation. Further studies are needed to elucidate the underlying molecular mechanism responsible for the different effects evoked by TRPV1 activation in MCF-7 and CF.41 cells. |
[
right
kwic]
(1)36  and |
(17)5 application |
(33)3 attachment |
(49)2 grading |
| (2)26 practice |
(18)5 data |
(34)3 course, |
(50)2 interventions |
| (3)22 trials |
(19)5 efficacy |
(35)3 examination, |
(51)2 literature |
| (4)19 trial |
(20)5 features |
(36)3 experience |
(52)2 measures |
| (5)14 research |
(21)5 outcome |
(37)3 information |
(53)2 nurse |
| (6)14 studies |
(22)5 picture |
(38)3 manifestations |
(54)2 observations |
| (7)10 use |
(23)5 relevance |
(39)3 significance |
(55)2 point |
| (8)8 parameters |
(24)5 symptoms |
(40)3 variables |
(56)2 practice, |
| (9)8 settings |
(25)5 translation |
(41)2 benefits |
(57)2 presentation, |
| (10)8 signs |
(26)5 trials, |
(42)2 cases |
(58)2 process |
| (11)8 study |
(27)5 utility |
(43)2 conditions |
(59)2 results |
| (12)7 examination |
(28)4 characteristics |
(44)2 context |
(60)2 sample, |
| (13)7 implications |
(29)4 evaluation |
(45)2 decision-making |
(61)2 situation |
| (14)7 presentation |
(30)4 management |
(46)2 decisions |
(62)2 situations, |
| (15)6 applications |
(31)4 outcomes |
(47)2 diagnosis |
(63)2 success |
| (16)6 course |
(32)4 signs, |
(48)2 findings |
(64)2 tooth |
add keyword
--- WordNet output for clinical ---